Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Vir Biotechnology (NASDAQ:VIR) issued its earnings results on Wednesday. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.18, FiscalAI reports. The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.98 million. The firm’s revenue for the quarter was down 178.3% compared to the same quarter last year. During the same period last year, the business posted ($1.17) EPS.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta phase III results are approaching: Vir expects ECLIPSE 1 top-line data in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027. The trials assess its combination regimen in treatment-naïve patients, patients switching from bulevirtide, and a head-to-head comparison with bulevirtide; management believes the program could offer deep viral suppression and less frequent dosing.
• VIR-5500 advanced toward pivotal development: Astellas and Vir say the prostate cancer T-cell engager achieved proof of concept based on combined clinical, safety, pharmacology, and biomarker data, and the FDA granted it fast-track designation for late-line mCRPC. The companies aim to begin multiple phase III studies in 2027, though Vir did not disclose response durability or detailed trial plans.
• Gilead collaboration adds funding and validates Vir’s platform: Vir received $65 million upfront plus a $25 million equity investment at a 30% premium, and is eligible for $45 million in near-term preclinical milestones, up to $1.74 billion in additional milestones, and tiered royalties. Gilead will take responsibility for later development, manufacturing, and commercialization of candidates; milestone and royalty payments are contingent.
• Vir reported $901 million in cash, equivalents, and investments at quarter-end, excluding the $90 million Gilead payment received in October. Management expects its cash to fund operations into the second half of 2028, based on its current operating plan.
• VIR-5818’s data update has been pushed out: Following FDA feedback on the monotherapy arm, Vir plans to add backfill cohorts in a more homogeneous patient population to refine dose and schedule. The study remains ongoing and the data set is incomplete, although combination dose optimization continues.

Vir Biotechnology Trading Down 6.4%

VIR stock opened at $11.02 on Friday. Vir Biotechnology has a 1-year low of $4.82 and a 1-year high of $12.19. The firm has a market cap of $1.86 billion, a PE ratio of -8.75 and a beta of 1.70. The business’s 50-day moving average price is $11.01 and its two-hundred day moving average price is $9.58.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Needham raised its price target to $20 from $18 and reiterated a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, a less negative view. Analyst ratings
• Positive Sentiment: Vir reported a third-quarter loss of $0.57 per share, narrower than analysts’ expected loss of $0.75–$0.80 and the $1.17 loss a year earlier. The company also said its cash runway extends into the second half of 2028. Q3 results and corporate update
• Neutral Sentiment: Vir plans to present Phase 3 hepatitis delta data for elebsiran and tobevibart at AASLD’s 2026 meeting. The data could be a significant catalyst, but its effect on the stock will depend on the results. AASLD data presentation
• Negative Sentiment: Revenue came in at negative $0.19 million, below analysts’ estimate of $0.98 million, and was down sharply year over year. The revenue shortfall may have overshadowed the narrower-than-expected loss. Q3 earnings coverage

Insider Activity

In other news, EVP Vanina de Verneuil sold 2,407 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70. Following the sale, the executive vice president owned 110,193 shares of the company’s stock, valued at $1,223,142.30. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on VIR. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research report on Thursday, August 6th. Raymond James Financial reiterated a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. HC Wainwright raised their target price on Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.14.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.